Table 1.
Demographics and clinical outcome measures of RA patients
| RA patients | P-value | |
|---|---|---|
| Number | 9 | |
| Sex (female/male) | 7/2 | |
| Age, year (mean ± SD, range) | 42·8 ± 11·5 (18–57) | |
| Duration of diagnosis (mean ± SD, range) | 11·3 ± 5·6 (3–17) | |
| Rheumatoid factor (positive/negative) | 8/1 | |
| EMS, min (mean ± SD, range) | ||
| Week 0 | 36·7 ± 99·3 (0–300) | |
| Week 24 | 0·0 ± 0·0 (0–0) | 0·300 |
| VAS pain score (median, IQR) | ||
| Week 0 | 73·0 (24·5–87·0) | |
| Week 24 | 31·0 (22·5–57·5) | 0·027 |
| Patient global assessment (median, IQR) | ||
| Week 0 | 67·0 (62·0–81·5) | |
| Week 24 | 40·0 (17·5–63·5) | 0·004 |
| Physician global assessment (median, IQR) | ||
| Week 0 | 65·0 (61·0–81·5) | |
| Week 24 | 40·0 (17·5–63·5) | 0·004 |
| Swollen joint score (median, IQR) | ||
| Week 0 | 11·0 (5·5–12·5) | |
| Week 24 | 6·0 (2·0–11·0) | 0·023 |
| ESR, mm/ h (median, IQR) | ||
| Week 0 | 72·0 (60·0–96·0) | |
| Week 24 | 59·0 (24·0–74·5) | 0·004 |
| CRP, mg/l (median, IQR) | ||
| Week 0 | 57·5 (36·1–67·7) | |
| Week 24 | 19·4 (4·1–53·9) | 0·039 |
| HAQ score (median, IQR) | ||
| Week 0 | 1·9 (0·5–2·7) | |
| Week 24 | 1·4 (0·4–2·1) | 0·004 |